Use este identificador para citar ou linkar para este item: http://rima.ufrrj.br/jspui/handle/20.500.14407/26418
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorGuimarães, Luanny Duque Ernesto-
dc.date.accessioned2026-09-24T14:06:31Z-
dc.date.available2026-09-24T14:06:31Z-
dc.date.issued2026-03-10-
dc.identifier.citationGUIMARÃES, Luanny Duque Ernesto. Síntese de Piperidinil-Alcoxi-1,3,4-Oxadiazóis Planejados como Inibidores de Colinesterases. 2026. 176 f. Dissertação (Mestrado em Química) - Instituto de Química, Universidade Federal Rural do Rio de Janeiro, Seropédica, 2026.pt_BR
dc.identifier.urihttp://rima.ufrrj.br/jspui/handle/20.500.14407/26418-
dc.description.abstractA Doença de Alzheimer (DA) pode ser definida como uma desordem neurodegenerativa progressiva e irreversível, afetando diretamente o funcionamento social e ocupacional. A enzima acetilcolinesterase (AChE) atua no controle dos níveis do neurotransmissor acetilcolina (ACh) na fenda sináptica, o qual está envolvido nos processos de aprendizagem e memória. A hipótese colinérgica possui como um de seus pontos principais a diminuição da atividade colinérgica pré-sináptica no cérebro do paciente com DA, assim, os inibidores colinérgicos buscam recompor a função colinérgica a partir do bloqueio da ação das enzimas acetil e butirilcolinesterase (BChE), responsáveis pela hidrólise da ACh. O atual trabalho consiste no planejamento, síntese e caracterização química e biológica de novos derivados piperidinil- alcoxi-1,3,4-oxadiazóis planejados pela hibridação molecular de inibidores de colinesterases que contém o núcleo 1,3,4-oxadiazol e de inibidores de colinesterases com o grupo alcoxi- piperidina, descritos por nosso grupo. Inicialmente buscou-se a otimização da rota sintética para a obtenção dos derivados planejados. O procedimento definido partia da síntese de dois blocos, as hidrazidas substituídas e os diferentes bromo-alcoxi-benzaldeídos, que então eram reagidos para a formação das N-acilidrazonas, que sofriam ciclização oxidativa com PhI(OAc)2 e posterior aminação com piperidina. Os rendimentos globais a partir dos blocos das hidrazidas e bromo-alcoxi-benzaldeídos variaram de 3,88 – 26,16%. A obtenção dos derivados se dividiu em três fases (1-a, 1-b e 2). A fase 1-a teve como principal objetivo definir a melhor extensão da cadeia alcoxi-amina e a sua posição da substituição no anel aromático, demonstrando que 2 metilenos espaçadores e a posição para seriam os ideais. A partir desta relação estrutura- atividade, na fase 1-b explorou-se a avalição dos grupos R substituindo o núcleo central oxadiazol, enquanto na fase 2 avaliou-se modificações na fenila ligada ao grupo alcoxi- piperidina. Todos os compostos avaliados mostraram-se ativos frente à AChE, com potências variando de 0,080 a 1,524 μM. Os compostos se mostraram menos potentes frente a BChE, com IC50 variando de 1,027 a 12,497 μM, originando seletividades de até 112 vezes (IC50 BChE/ IC50 AChE). Investigações do perfil de interação teórico dos derivados com a AChE e BChE, através de ancoragem molecular, também foram realizadaspt_BR
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESpt_BR
dc.languageporpt_BR
dc.publisherUniversidade Federal Rural do Rio de Janeiropt_BR
dc.subject1,3,4-oxadiaxóispt_BR
dc.subjectAlzheimerpt_BR
dc.subjectinibidores de colinesterasespt_BR
dc.subject1,3,4-oxadiazolespt_BR
dc.subjectAlzheimer'spt_BR
dc.subjectcholinesterase inhibitorspt_BR
dc.subjectmolecular hybridizationpt_BR
dc.subjectmolecular dockingpt_BR
dc.titleSíntese de Piperidinil-Alcoxi-1,3,4-Oxadiazóis Planejados como Inibidores de Colinesterasespt_BR
dc.title.alternativeSynthesis of Piperidinyl-Alkoxy-1,3,4-Oxadiazoles Designed as Cholinesterase Inhibitorsen
dc.typeDissertaçãopt_BR
dc.description.abstractOtherAlzheimer's Disease (AD) can be defined as a progressive and irreversible neurodegenerative disorder, directly affecting social and occupational functioning. The enzyme acetylcholinesterase (AChE) acts in controlling the levels of the neurotransmitter acetylcholine (ACh) in the synaptic cleft, which is involved in learning and memory processes. One of the main points of the cholinergic hypothesis is the decrease in pre-synaptic cholinergic activity in the brain of AD patients; thus, cholinergic inhibitors aim to restore cholinergic function by blocking the action of the enzymes acetyl- and butyrylcholinesterase (BChE), which are responsible for ACh hydrolysis. The present work consists of the design, synthesis, and chemical and biological characterization of novel piperidinyl-alkoxy-1,3,4-oxadiazole derivatives designed through the molecular hybridization of cholinesterase inhibitors containing the 1,3,4-oxadiazole core and cholinesterase inhibitors with the alkoxy-piperidine group, previously described by our group. Initially, we sought to optimize the synthetic route to obtain the planned derivatives. The established procedure started with the synthesis of two building blocks, substituted hydrazides and different bromo-alkoxy-benzaldehydes, which were then reacted to form N-acylhydrazones, followed by oxidative cyclization with PhI(OAc)2 and subsequent amination with piperidine. Overall yields from the hydrazide and bromo-alkoxy- benzaldehyde blocks ranged from 3.88 – 26.16%. The synthesis of the derivatives was divided into three phases (1-a, 1-b, and 2). Phase 1-a primarily aimed to define the optimal length of the alkoxy-amine chain and its position of substitution on the aromatic ring, demonstrating that 2 methylene spacers and the para position were ideal. Based on this structure-activity relationship, Phase 1-b explored the evaluation of R groups substituting the central oxadiazole core, while Phase 2 evaluated modifications on the phenyl ring linked to the alkoxy-piperidine group. All evaluated compounds were found to be active against AChE, with potencies ranging from 0.080 to 1.524 μM. The compounds proved to be less potent against BChE, with IC50 values ranging from 1.027 to 12.497 μM, yielding selectivities up to 112-fold (IC50 BChE / IC50 AChE). Investigations into the theoretical interaction profile of the derivatives with AChE and BChE via molecular docking were also performedpt_BR
dc.contributor.advisor1Kümmerle, Arthur Eugen-
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/5598000938584486pt_BR
dc.contributor.advisor-co1Lacerda, Renata Barbosa-
dc.contributor.advisor-co1IDhttps://orcid.org/0000-0002-6185-3408pt_BR
dc.contributor.advisor-co1Latteshttp://lattes.cnpq.br/2068820144272983pt_BR
dc.contributor.referee1Kümmerle, Arthur Eugen-
dc.contributor.referee1Latteshttp://lattes.cnpq.br/5598000938584486pt_BR
dc.contributor.referee2Pinheiro, Pedro de Sena Murteira-
dc.contributor.referee2IDhttps://orcid.org/0000-0003-4148-4243pt_BR
dc.contributor.referee2Latteshttp://lattes.cnpq.br/5967618384293645pt_BR
dc.contributor.referee3Carneiro, Leonardo Simões de Abreu-
dc.contributor.referee3IDhttps://orcid.org/0000-0001-9095-2678pt_BR
dc.contributor.referee3Latteshttp://lattes.cnpq.br/1574550584027810pt_BR
dc.creator.Latteshttp://lattes.cnpq.br/0784163242464797pt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentInstituto de Químicapt_BR
dc.publisher.initialsUFRRJpt_BR
dc.publisher.programPrograma de Pós-Graduação em Químicapt_BR
dc.relation.references1) KRAEPELIN, E. Psychiatrie: Ein Lehrbuch für Studierende und Ärzte, Klinische Psychiatrie [Psychiatry: a study book for students and doctors, clinical psychiatry]. Liepzig, Barth, v. 1915, 1910. 2) ARBO, Bruno Dutra. Efeitos neuroprotetores do 4’-clorodiazepam em modelos experimentais de Doença de Alzheimer in vitro e sobre o desenvolvimento neuronal. 2016. 201 f. Tese (Doutorado) - Curso de Fisiologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, 2016 3) Alzheimer's Association. Disponível em: Acesso em: 30 de dezembro. 2025 4) LIU, Pei-Pei et al. History and progress of hypotheses and clinical trials for Alzheimer’s disease. Springernature, [s. l], v. 29, n. 4, p. 1-22, ago. 2019. 5) WAIKER, Digambar Kumar et al. Development and Evaluation of Some Molecular Hybrids of N-(1-Benzylpiperidin-4-yl)-2-((5-phenyl-1,3,4-oxadiazol-2-yl)thio) as Multifunctional Agents to Combat Alzheimer’s Disease. Acs Omega, [S.L.], v. 8, n. 10, p. 9394-9414, 2 mar. 2023. American Chemical Society (ACS). http://dx.doi.org/10.1021/acsomega.2c08061. 6) CHOUBEY, P.K.; et al. Design, synthesis, and evaluation of N-benzylpyrrolidine and 1,3,4-oxadiazole as multitargeted hy brids for the treatment of Alzheimer’s disease. Bioorg. Chem., 2021, 111, 104922. 7) KNOPMAN, David S. et al. Alzheimer disease. Nature Reviews, [s. l], v. 33, n. 7, p. 1- 27, 2021. 8) CHÉTELAT, Gaël et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias. Lancet Neurol, [s. l], v. 19, p. 951- 962, nov. 2020. 110 9) ZANG, Wei-Biao et al. Curcumin hybrid molecules for the treatment of Alzheimer's disease: structure and pharmacological activities. European Journal Of Medicinal Chemistry, [S.L.], v. 265, p. 116070, http://dx.doi.org/10.1016/j.ejmech.2023.116070 10) QIAN, Chengyuan et al. Multifunctional nano-enabled delivery systems in Alzheimer's disease management. Biomaterials Science, [S.L.], v. 8, n. 20, p. 5538 5554, 2020. Royal Society http://dx.doi.org/10.1039/d0bm00756k. of Chemistry (RSC). 11) KARRAN, Eric; STROOPER, Bart de. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nature Reviews Drug Discovery, [s. l], v. 21, p. 306-318, 2022. 12) ZHANG, Yun et al. Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future. Signal Transduction And Targeted Therapy, [s. l], v. 8, n. 248, p. 1-26, jun. 2023. 13) MATTKE, S., OZAWA, T., & HANSON, M. (2025). Implications of Treatment Duration and Intensity on the Value of Alzheimer's Treatments. Clinical Trials on Alzheimer's Disease, 17, S303-S304. 14) FERREIRA, Larissa de Almeida Peixoto. Síntese e avaliação farmacológica de novas 3-(imidazo[1,2-a]piridinas)-cumarinas planejadas para o tratamento da Doença de Alzheimer. 2021. 185 f. Dissertação (Mestrado) - Curso de Química, Universidade Federal Rural do Rio de Janeiro, Seropédica, 2021. 15) MASUDA-SUZUKAKE, Masami et al. Animal models of tau propagation in Alzheimer's disease. Neuroscience Research, [S.L.], v. 220, p. 104960, nov. 2025. Elsevier BV. http://dx.doi.org/10.1016/j.neures.2025.104960. 16) DE SÁ CAVALCANTI, José Luiz; ENGELHARDT, Eliasz. Aspectos da fisiopatologia da doença de Alzheimer esporádica. Rev Bras Neurol, v. 48, n. 4, p. 21-29, 2012. 111 17) RAJASEKHAR, K.; GOVINDARAJU, Thimmaiah. Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer's disease. Rsc Advances, [S.L.], v. 8, n. 42, p. 23780-23804, 2018. Royal Society of Chemistry (RSC). http://dx.doi.org/10.1039/c8ra03620a. 18) BAI, Renren et al. Oxidative stress: the core pathogenesis and mechanism of alzheimer’s disease. Ageing Research Reviews, [S.L.], v. 77, p. 101619, maio 2022. Elsevier BV. http://dx.doi.org/10.1016/j.arr.2022.101619. 19) DAVIES, P. & MALONEY, A. J. Selective loss of central cholinergic neurons in Alz heimer’s disease. Lancet 2, 1403 (1976). 20) ELGHAZAWY, Nehal H. et al. Discovery of New1,3,4-Oxadiazoles with Dual Activity Targetingthe Cholinergic Pathwayas Effective Anti-Alzheimer Agents. Acs Chemical Neuroscience, [s. l], v. 13, p. 1187-2051, abr. 2022. 21) KIRAN, Pidugu Venkata Ravi et al. Design and development of benzyl piperazine linked 5-phenyl-1,2,4-triazole-3-thione conjugates as potential agents to combat Alzheimer’s disease. Bioorganic Chemistry, [S.L.], v. 139, p. 106749, out. 2023. Elsevier BV. http://dx.doi.org/10.1016/j.bioorg.2023.106749. 22) PHILPOTEDUCATION. Applications and skills. Disponível em: https://www.philpoteducation.com/mod/book/view.php?id=832&chapterid=286 9#/. Acesso em: 19/04/2025. 23) WU, Jie et al. Design, synthesis and biological evaluation of novel carbamates as potential inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorganic & Medicinal Chemistry, [S.L.], v. 28, n. 5, p. 115324, mar. 2020. Elsevier BV. http://dx.doi.org/10.1016/j.bmc.202. 24) GOULART, Paula do N. et al. Butirilcolinesterase - BuChE: um Potencial Alvo para o Desenvolvimento de Fármacos para o Tratamento da Doença de Alzheimer. Revista Virtual de Química, RJ, v. 13, n. 1, p. 1-37, nov. 2021. 112 25) NICOLET, Yvain et.al. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. Journal of Biological Chemistry, v. 278, n. 42, p. 41141- 41147, 2003. 26) JING, Lanlan et al. Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors. Drug Discovery Today, [S.L.], v. 24, n. 2, p. 629-635, fev. 2019. Elsevier BV. http://dx.doi.org/10.1016/j.drudis.2018.11.012 27) SHARMA, Kamlesh. Cholinesterase inhibitors as Alzheimer's therapeutics (Review). Molecular Medicine Reports, [S.L.], p. 1479-1487, 11 jun. 2019. Spandidos Publications. http://dx.doi.org/10.3892/mmr.2019.10374. 28) FRANCO, Daiana de Fatima Portella. SÍNTESE E AVALIAÇÃO FARMACOLÓGICA DE NOVOS 3-AMINO 1,2,4-TRIAZÓIS COMO INIBIDORES DE ENZIMAS ENVOLVIDAS NA DOENÇA DE ALZHEIMER. 2020. 283 f. Tese (Doutorado) - Curso de Química, Universidade Federal Rural do Rio de Janeiro, Seropédica, 2020. 29) AMARAL, Alexandre Teixeira do et al. ADUCANUMAB NO TRATAMENTO DA DOENÇA DE ALZHEIMER. Recima21 - Revista Científica Multidisciplinar - Issn 2675 6218, [S.L.], v. 4, n. 9, p. 1-8, 15 set. 2023. RECIMA21 - Revista Cientifica Multidisciplinar. http://dx.doi.org/10.47820/recima21.v4i9.4023. 30) Alzheimer’s Association. 2025 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2025; 21(5) 31) DUARTE, Carolina D.; BARREIRO, Eliezer J.; FRAGA, Carlos A.M.. Privileged Structures: A Useful Concept for the Rational Design of New Lead Drug Candidates. Mini- Reviews In Medicinal Chemistry, [s. l], v. 7, p. 1108-1119, 2007 32) EVANS, B. E. et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. Journal Of Medicinal Chemistry, [S.L.], v. 31, n. 12, p. 2235-2246, 1 dez. 1988. American Chemical Society (ACS) 33) PATCHETT, Arthur A.; NARGUND, Ravi P.. Chapter 26. Privileged structures — An update. Annual Reports In Medicinal Chemistry, [S.L.], p. 289-298, 2000. Elsevier. 113 34) SILVA, T. F.. Medicinal Chemistry Approaches to Design of Drug Prototypes. Revista Virtual de Química, [S.L.], v. 5, n. 5, p. 921-933, 2013. Sociedade Brasileira de Quimica (SBQ). 35) GONSALVES, Arlan de Assis et al. PROPOSTA DE SÍNTESE ONE-POT: práticas experimentais de química orgânica e medicinal a partir da preparação do heterociclo tiazol. Química Nova, [S.L.], p. 1-7, 2025. Sociedade Brasileira de Quimica (SBQ). 36) VENDRUSCULO, Vinicius. SÍNTESE DE HÍBRIDOS MOLECULARES BASEADOS EM TETRAHIDROINDOLONAS, TETRAHIDROINDAZOLONAS E DIHIDROPIRIMIDINONAS VIA REAÇÕES DO TIPO CLICK. 2025. 315 f. Tese (Doutorado) - Curso de Química, Universidade Federal do Rio Grande do Sul, Porto Alegre, 2025. 37) VICTORY, Matias Ezequiel. SÍNTESE DE 1,3-DIINOS CONTENDO QUINOLINA COMO BLOCO DE CONSTRUÇÃO E ESTUDO FOTOFÍSICO. 2025. 149 f. Dissertação (Mestrado) - Curso de Química, Universidade Federal do Rio Grande do Sul, Porto Alegre, 2025. 38) SILVA, Wellington da; BISPO, Marcelle de Lima Ferreira; ORSATO, Alexandre. Indole: a versatile and promising heterocycle for the discovery of novel antibacterial and antifungal agents. Revista Virtual de Química, [S.L.], v. 14, n. 4, p. 612-636, 2022. Sociedade Brasileira de Quimica (SBQ). 39) LI, Z.; ZHAN, P.; LIU, X.. 1,3,4-Oxadiazole: a privileged structure in antiviral agents. Mini-Reviews In Medicinal Chemistry, [S.L.], v. 11, n. 13, p. 1130-1142, 1 nov. 2011. Bentham Science Publishers Ltd. 40) SOUZA, Diego Ramon dos Santos. Síntese, caracterização e estudo antibacteriano de 1, 3, 4 - oxadiazóis derivados de N acilhidrazonas. 2013. 43 f. TCC (Graduação) - Curso de Farmácia, Universidade Federal de Campina Grande, Cuité, 2013 41) DESAI, Nisheeth et al. Oxadiazole: a highly versatile scaffold in drug discovery. Archiv Der Pharmazie, [S.L.], v. 355, n. 9, p. 1-44, 16 maio 2022. Wiley. http://dx.doi.org/10.1002/ardp.202200123. 114 42) DU, Yao et al. Review on the Synthesis and Performance for 1,3,4 Oxadiazole-Based Energetic Materials. Propellants Explos. Pyrotech., [s. l], v. 46, p. 860-874, 2021. 30. 43) NASEEM, Saira et al. Therapeutic potential of 1,3,4-oxadiazoles as potential lead compounds for the treatment of Alzheimer's disease. Rsc Advances, [S.L.], v. 13, n. 26, p. 17526-17535, 2023. http://dx.doi.org/10.1039/d3ra01953e. Royal Society of Chemistry (RSC). 55 31. 44) GUO, Yong et al. Synthesis and Biological Evaluation of Honokiol Derivatives Bearing 3- ((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)oxazol 2(3H)-ones as Potential Viral Entry Inhibitors against SARS-CoV-2. Pharmaceuticals, [s. l], v. 885, n. 14, p. 1-16, 2021. 45) ALMEIDA, Nathália Rodrigues de. SÍNTESE E AVALIAÇÃO DA ATIVIDADE BIOLÓGICA DE HIDRAZONAS E 1,3,4 OXADIAZÓIS A PARTIR DE LIPÍDEOS FENÓLICOS. 2017. 115 f. Dissertação (Mestrado) - Curso de Química, Universidade Federal do Mato Grosso do Sul, Campo Grande, 2017. 46) ZHANG J, et al. Synthesis and evaluation of coumarin/1,2,4-oxadiazole hybrids as selective BChE inhibitors with neuroprotective activity. J Asian Nat Prod Res 21:1090–1103. 2019. https:// doi. org/ 10. 1080/ 10286 020. 2018. 14925 66. 47) SAFFOUR, Sana; et al. Novel Quinoline-1,3,4-Oxadiazole Derivatives for Alzheimer’s Disease: Their Design, Synthesis, and In-Vitro and In-Silico Investigations, Current Medicinal Chemistry; V. 31, 2024. DOI: 10.2174/0109298673333159240815061359. 48) SHAH, Moksh et al. Oxadiazoles as multi-target therapeutic agents in Alzheimer’s Disease: a review of cholinesterase, mao, β-secretase, and aβ aggregation inhibition. Journal Of Saudi Chemical Society, [S.L.], v. 29, n. 5, p. 1-61, nov. 2025. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s44442-025-00036-8. 49) NASAB, N. H. et al. Exploring the anti-Alzheimer poten tial: design, synthesis, biological activity, and molecular docking study of benzothiazol-1,3,4-oxadiazole-acetamide compounds. J Mol Struct 1318:139307. 2024. https:// doi. org/ 10. 1016/j. molst ruc. 2024. 139307 73. 115 50) HUSSAIN, R. et al. Inibidores promissores de acetilcolinesterase e butirilcolinesterase: estudos enzimáticos in vitro e de acoplamento molecular in silico de derivados híbridos de imidazopiridina contendo oxadiazol à base de benzotiazol. Results Chem 7:101503. 2024. https://doi.org/10.1016/j.rechem.2024.101503. 51) KILIC-KURT, Z. et al. Some heterocycles connected to substituted piperazine by 1,3,4- oxadia zole linker: design, synthesis, anticholinesterase and antioxidant activity. J Mol Struct 1321:139854 .2025. https:// doi. org/ 10. 1016/j. molst ruc. 2024. 139854 52) DE SOUZA, Gabriela Alves et al. Discovery of novel dual-active 3-(4 (dimethylamino)phenyl)-7-aminoalcoxy-coumarin as potent and selective acetylcholinesterase inhibitor and antioxidant. Journal of enzyme inhibition and medicinal chemistry, v. 34, n. 1, p. 631-637, 2019. 53) SHAMSIMEYMANDI, Reza et al. Design, synthesis, biological evaluation, and molecular dynamics of novel cholinesterase inhibitors as anti‐Alzheimer's agents. Archiv Der Pharmazie, [S.L.], v. 352, n. 7, p. 1800352, 28 maio. 2019. Wiley. http://dx.doi.org/10.1002/ardp.201800352. 54) YAMADA, S.; MORIZONO, D.; YAMAMOTO, K. Mild oxidation of aldehydes to the corresponding carboxylic acids and esters: alkaline iodine oxidation revisited. Tetrahedron Letters, v. 33, n. 30, p. 4329-4332, 1992. 55) YU, Wenquan et al. I2-Mediated Oxidative C–O Bond Formation for the Synthesis of 1,3,4- Oxadiazoles from Aldehydes and Hydrazides. The Journal Of Organic Chemistry, [s. l], v. 78, p. 10337-10343, set. 2013. 56) TAHA, Muhammad et al. Synthesis of new oxadiazole derivatives as a-glucosidase inhibitors. Bioorganic & Medicinal Chemistry, [s. l], v. 23, p. 4155-4162, set. 2015. 57) LIMA, P. C. Síntese e Avaliação das Propriedades Antinociceptivas de Novas Acilidrazonas Derivadas do Safrol. Dissertação de Mestrado, IQ - UFRJ - Rio de Janeiro, 1998. 116 58) KONKEN, C. P. et al. Development of symmetric O-BODIPYs with different optical properties as building blocks for the synthesis of ligands for multimodal imaging. Dyes and Pigments, v. 158, p. 88–96, nov. 2018. 59)CAREY, F. A. SUNDBERG, R. J. Advanced Organic Chemistry, Part A: Structure and Mechanisms, 5a Ed., New York: Springer, 2008. 60) KÜMMERLE, A. E.; et al. Design, Synthesis, and Pharmacological Evaluation of N- Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase-4 Inhibitors. J. Med. Chem. 2012, 55 (17), 7525– 7545. https://doi.org/10.1021/jm300514y. 61) PALLA, G.; et al. Conformational study on N-acylhydrazones of aromatic-aldehydes by NMR-spectroscopy. Gazzetta Chimica Italiana, v. 112, p. 339-341, 1982. 62) Franco, D. P.; et al. Synthesis and Pharmacological Evaluation of Novel 1,5-Disubstituted- 3-Amino-1,2,4-Triazoles Designed as Multitarget Directed Ligands for Alzheimer’s Disease Targets. ACS Omega 2026. https://doi.org/10.1021/acsomega.5c09002. 63) SUMRAN, Garima; RANI, Chinu; AGGARWAL, & Ranjana. Efficient synthesis of new oxadiazole-thiazole hybrids using (diacetoxyiodo)benzene. Indian Journal Of Chemistry, [s. l], v. 59, p. 85-92, jan. 2020. 64) SIHAG, Monika; KINGER, Mayank; ANEJA, Deepk Kumar. A Focused Review on Oxidation of Hydrazones Using Hypervalent Iodine Reagents. Chemistryselect, [s. l], v. 10, p. 1-53, jan. 2025 65) Nadur, N. F.; et al. Design, Synthesis, and Biological Evaluation of Novel Multitarget 7- Alcoxyamino-3-(1,2,3-Triazole)-Coumarins as Potent Acetylcholinesterase Inhibitors. Pharmaceuticals 2025, 18 (9). https://doi.org/10.3390/ph18091398. 117 66)CLAYDEN, J.; GREEVES, N.; WARREN, S. Organic Chemistry. 2a Ed., New York: Oxford University Press, 2001. 67) HARNED, Andrew M.. Asymmetric oxidative dearomatizations promoted by hypervalent iodine(III) reagents: an opportunity for rational catalyst design?. Tetrahedron Letters, [S.L.], v. 55, n. 34, p. 4681-4689, ago. 2014. Elsevier BV. http://dx.doi.org/10.1016/j.tetlet.2014.06.051. 68)BHUJABAL, Yuvraj B. et al. Pd/PTABS: catalyst for efficient c⨲h (hetero)arylation of 1,3,4⠰oxadiazoles using bromo(hetero)arenes. Asian Journal Of Organic Chemistry, [S.L.], v. 8, n. 2, p. 289-295, 18 jan. 2019. Wiley. http://dx.doi.org/10.1002/ajoc.201800713. 69) GELIN, Loris et al. Direct Palladium‐Catalyzed C5‐Arylation of 1,3,4‐Oxadiazoles with Aryl Chlorides Promoted by Bis(di‐isopropylphosphino) Ferrocene. European Journal Of Organic Chemistry, [S.L.], v. 27, n. 21, p. 1-6, 22 maio 2024. Wiley. http://dx.doi.org/10.1002/ejoc.202400212. 70) KUMAR, Amit et al. Post-Ugi gold-catalyzed diastereoselective domino cyclization for the synthesis of diversely substituted spiroindolines. Beilstein Journal Of Organic Chemistry, [S.L.], v. 9, p. 2097-2102, 14 out. 2013. Beilstein Institut. http://dx.doi.org/10.3762/bjoc.9.246. 71)BAKARE, Sneha Prasad; PATIL, Mahendra. Palladium catalyzed direct C–H arylation of 1,3,4-oxadiazole using ligand combination approach. Tetrahedron, [S.L.], v. 155, p. 133885, abr. 2024. Elsevier BV. http://dx.doi.org/10.1016/j.tet.2024.133885. 72) ELLMAN, G. L.; COURTNEY, K. D.; ANDRES, V.; FEATHERSTONE, R. M. A new colorimetric and rapid determination acetylcholinesterase activity. Biochemical pharmacology, v. 7, n. 2, p. 88-95, 1961. 73) GERLITS, Oksana et al. A new crystal form of human acetylcholinesterase for exploratory room-temperature crystallography studies. Chemico-Biological Interactions, [S.L.], v. 309, p. 108698, ago. 2019. Elsevier BV. http://dx.doi.org/10.1016/j.cbi.2019.06.011. 118 74) SUSSMAN, Joel L. et al. Atomic Structure ofAcetyicholinesterase from Torpedo cal fornica: A Prototypic Acetyicholine-Binding Protein. Science, [s. l], v. 253, p. 872 879, ago. 1991. 75) GRIGOREV, Veniamin et al. Structural fractal analysis of the active sites of acetylcholinesterase from various organisms. Journal Of Molecular Graphics And Modelling, [S.L.], v. 116, p. 108265, nov. 2022. Elsevier BV. http://dx.doi.org/10.1016/j.jmgm.2022.108265. 76) ACHON, Florian et al. Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-alzheimer's drugs targeting acetyl- and butyryl-cholinesterase. Biochemical Journal, [S.L.], v. 453, n. 3, p. 393-399, 12 jul. 2013. Portland Press Ltd.. http://dx.doi.org/10.1042/bj20130013pt_BR
dc.subject.cnpqQuímicapt_BR
Aparece nas coleções:Mestrado em Química

Se for cadastrado no RIMA, poderá receber informações por email.
Se ainda não tem uma conta, cadastre-se aqui!

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
LUANNY DUQUE ERNESTO GUIMARÃES.pdf12,46 MBAdobe PDFAbrir


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.